FDA Panel Backs Female Viagra

A panel of medical experts has recommended that the U.S. Food and Drug Administration approve the so-called “female Viagra” drug that is designed to boost the libido of women.

Flibanserin, the new drug, has been rejected on two previous occasions by the FDA since 2010 due to concerns that its side effects outweigh the benefits.

However, the vote of 18-6 was considered a wide margin of victory for the drug, since the regulatory agency often times adopts the advice of its expert groups and the same group had voted twice before against flibanserin.

Critics however raised a number of questions about flibanserin’s efficacy. They also have accused the pharmaceutical industry of making up hypoactive sexual desire disorder, a medical condition that the drug is supposedly to be used to treat.

Women in the U.S. are one step closer to having female Viagra. The new drug is a daily pill that is produced by Sprout Pharmaceutical that is designed to treat a women’s low libido in women that are premenopausal.

To date the drug is still not approved for sale, but pressure to make in available is growing.

On Thursday, the advisory panel recommended the drug on the condition Sprout could figure out how to lower the patient’s safety risks.

That could mean that medical professionals might have to take a training course prior to being allowed to write a prescription for the drug or make women who want the medication to sign saying they will not used alcohol or birth control while suing the pink women’s Viagra pill.

About one out of five women who used the drug have had side effects with the most common being dizziness, low blood pressure and fainting.

While men’s sexual performance is enhanced by Viagra, by the increase of blood flow, the women’s version works on raising the dopamine level in women’s brains.

It is not clear if the FDA is going to take the advice of its advisory panel particularly since the regulatory agency has questions the effectiveness of the drug and its safety before. The results of the pill’s clinical trials have been mediocre.

 

Latest News

Deutsche Bank AG Boosts Cobham plc  Price Target to GBX 175
Deutsche Bank AG Boosts Cobham plc Price Target to GBX 175
Eco Animal Health Group Plc  Earns “Buy” Rating from Peel Hunt
Eco Animal Health Group Plc Earns “Buy” Rating from Peel Hunt
Pool Corp.  Downgraded by Zacks Investment Research
Pool Corp. Downgraded by Zacks Investment Research
Goldman Sachs Group Inc. Lowers Marvell Technology Group Ltd.  to Sell
Goldman Sachs Group Inc. Lowers Marvell Technology Group Ltd. to Sell
Goldman Sachs Group Inc. Lowers Marvell Technology Group Ltd.  to Sell
Goldman Sachs Group Inc. Lowers Marvell Technology Group Ltd. to Sell
Bojangles Inc.  Major Shareholder International Corp/Ma Advent Sells 6,616,889 Shares of Stock
Bojangles Inc. Major Shareholder International Corp/Ma Advent Sells 6,616,889 Shares of Stock


Leave a Reply

 
 
© 2006-2016 The Vista Voice. Subscribe